Mohamed S. Arredouani, PhD
Beth Israel Deaconess Hospital - Boston, Massachusetts

Dr. Arredouani began his studies at the Moulay Ismail University in Meknes, Morocco, where he graduated with a degree in biology. He then shifted continents to attend the Saint Petersburg State Polytechnic University and the Institute of Experimental Medicine of the Russian Academy of Medical Sciences, Saint Petersburg, Russia. There he received a M.Sc. Degree in Molecular Biology. He completed his academic studies with a PhD in Immunology, from the Catholic University of Leuven in Belgium. He made his way to the United States and joined Harvard School of Public Health as a Research Fellow. It was there that he investigated immune responses to viral and bacterial infections.

While completing his fellowship, Dr. Arredouani became interested in practical applications of immunology toward cancer, with specific opportunities in prostate cancer. He is especially interested in translating new breakthroughs in immune tolerance for the purpose of improving prostate cancer vaccines. Dr. Arredouani feels that funding for prostate cancer research through the Prostate Cancer Foundation is “one of the best things that have happened to prostate cancer patients in the last 15 years.” The importance of the funding is that recipients not only perform basic research in the field, but can develop clinical trials to test new therapies.

Aside from his work in the lab at Beth Israel Deaconess Medical Center, Dr. Arredouani enjoys spending time with his wife and two sons, ages 3 and 7 years old. The extra-curricular education of his children is a sort of a second job to him. Dr. Arredouani’s hobbies include calligraphy, reading, listening to music, playing tennis, table tennis, soccer, snooker and learning new languages.

While Dr. Arredouani enjoys his personal time a great deal, he remains extremely devoted to finding a cure for prostate cancer. He is especially grateful for the efforts of the PCF in supporting young investigators, such as himself. "This is a wise investment in the future," he says, "and a boost of hope for patients who look forward to a cure."